2017. ACR/ARHP Annual Meeting – Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada

Foo J, Rodriguez Heredia JM, Polanco Sánchez C, Mtibaa M, KH Herrmann KH, Alemao E, Postema R,  Baerwald C. Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada. Arthritis Rheumatol. 2017;69(suppl 10). Abstract #1465. Presented at: ACR/ARHP Annual Meeting 2017; November 03-08, 2017; San Diego, CA, USA.